Free Motion for Leave to File - District Court of Delaware - Delaware

Case 1 :04-cv-01334-KAJ Document 35-3 Filed O4/06/2006 Page 1 of 2
RT. 1 1 3 NORTH —F1NA1- _ _
G EO RG ETOWN , D E 19 947 (D0301 ) _‘_.‘` Z
M NAME PATIENT i.¤.;nooM No. oocron 1 cnouv NAME ` :"="`
JORDAN, DONALD 095723 DR. BURNS
me 1.0. No. one cottzcnso one Rscmvep pm; or nevoai Ace sex
100751809 12/29/2005 12/29/2005 23:42 01/01/2006 10:46 54 M
Test Description Result Abnormal Reference Units
E: 2·‘t ·`/== J -¤7=.¤ 2. ‘./. A A zl- -:...1.;; .-.‘‘ ‘222? -;. .2 ‘2..? .5 -fi--= ·‘._ t ..= 1:1Q :·22; ·‘/- i‘/ 2`E`2 ’-/
Albumin 4.3 3.2-5.2 gm/dl
.. 2 .22· - . ;¤.= _ :·: ‘·2‘
A/G Ratio 1.4 1.1-2.9
:.1- .`. 2 ;...; :.. ..-
BILIRUBIN, DIRECT 0.1 0.0-0.3 MG/DL
{ _. _ g- _j 2 :": '= Y,.] ;: ·_ if': ·‘·‘· ._.; ll 2 -· -5 _ _ ._:.’ __;:_:;:: ____ E __f I _ .: E,-,:_:j L- ,Z‘ ,_ ·- - _:2::-::=,;;__,jE;:_;§E::_:§j_. '· _ '·
· -=·-· ' --‘‘ ‘ ·.··_ - -.-‘--- 2 J ,. . = ;2-.¤?;·;‘;2‘- Q 2. ·. .___ :--2;%- -2 _..· ;. ··‘-·=·= 2 2 _. .; =._. :2;z;.;2:;__...2:; -_ __ _ __ ‘ 2 ...‘ ‘-_·_-..._- ; . =--. .¤j=;-=¤.2.;=:._;.2;..22.;.;e22 ==2; ;=2.2;2 -‘-.. 2 2 .·-·2 2; .--=2- _. -.
AST SG OT 7
_=._. d __/=. _._... . .__.. __..._ _.__._/....__... ._.._ y ._._ __ .._.... ....__ _ .:.. /.__ __ __ _ g t u .. “" _ ____
n PROTIME n n n n 10.5 n 10.1-13.6sec
._..= 125 -‘.`. 1 .é‘ .22 Q :2- ` I ‘ - -2" . ‘ -2 if 2i’ - ‘ -·‘‘-‘ L '·i‘ I TE ’i- ‘’".`·‘‘ z ‘‘·‘ ‘`‘·:`’ ‘ ‘‘=` - `‘`‘ T ‘-i· Zi _-.·; ‘`·· I `2.-- . i .· " 2--·
" `"’‘’"` ` ‘`‘`"`‘’` `‘‘``‘` ` ‘‘’‘`‘’"`‘’‘’‘’‘’"’‘’’‘‘ i’` *** * * ******** *** ** * * ** ******* **** ** * ‘ ‘``‘ " 2 ‘
CLINICAL INDICATIONS FOR INR USE REFERENCE RANGE
Prophyi axi s or treatment of venous th rombosi s, 2 .0 — 3 . O
systemic embolization, or (therapeutic range)
treatment of pulmonary embolus.
Hi gh- ri sk patients wi th mechanica1 heart valves. 2.5 — 3. 5
**********************************
NOTE : INR va] ues below 2 .0 in patients on warfarin therapy would
be considered s ub—the rapeuti c for the above condi ti ons.
No rmai subjects NOT t reated wi th warfarin wi ii have INR val ues
in the range of: O.87 — 1.19
an EPATITI c Notvprs nlln I see Betow I
... ...`2-. ’’‘``$ ’i‘ E .:=2‘.i 2—·‘ ? ‘2‘‘ i ‘’- --‘-’= 3 .`§E2 ¤=. ·`-‘2 = `‘2‘
HEP.C,RNA,bDNA,QNT I 2884120 <615 IU/mL
***************** ************* ****1***************************************
Test# 33 3 5 (Hep . C RNA/Vi ra] load , bDNA) pe rfo rmed using Bayer bDNA
AS S ay .
****************************************************************************
Test# 2161 (Hepatitis C Genotype) performed using Baye r Versant
L I PA A S S ay .
**************************************************************************
Printed: O1/O2/2006 14:28 Continued on Next Page Pg; 1

U Case 1:04-cv—01334-KAJ Document 35-3 Filed 04/06/2006 Page 2 of 2
'_`‘ i . ..__ - _'-' L _'-` an ;_- Qfin `_ - _ . U - =__ _‘`-- _ .- __._ .-'_ ·_`-. , _- -·`_.· I `-‘- .‘`·
RT. 113 NORTH -FINAL-
.=‘- ; li`- · .
GEORGETOWN, DE 19947 (D0301)
é NAME PATTENT LD./ROOM NO. DOCTOR/ GROUP NAME
JORDAN, DONALD 095723 DR. BURNS
LAB LD. NO. DATE COLLECTED DATE RECEKVED DATE OF REPORT AGE SEX
100751809 12/29/2005 12/29/2005 23:42 01/O1/2006 10:46 54 M
Test Description Result Abnormal Reference Units
NOTE: Specimen submitted was moderately lipemic. Please evaluate
all results with caution.
***~A·~k~A·*·k*·k·k~A·T':·A·*·k·A•1:*»'r*·k~k·k·k·Ar·k·A·*x\·1%*·k·k·k*·A·*·k—k~k*kirkTk·k1*:sk*ks\·>\··k*A··k~k*~k1‘¢$‘c»‘c*·k~k*****1¢·k·k~k+¢ic>\·
Hepatitis C genotype (test#1421) was evaluated and its performance
characteristics determined by BioReference Laboratories. It has not been
cleared or approved by the FDA, but such clearance or approval is not
necessary. It should not be regarded as investigational or for research.
The laboratory is certified under the Clinical Laboratory Improvement Act
of 1988 (CLIA) as qualified to perform high—complexity clinical testing.
**·A··k*1¢*$r·k*kk***·A··k**2****·k·k**·k·k·A··A··k*·k**k‘A·§.··k*·k#*·k*·k·A·*·k·k**·k*1\··k*·k*·k**A·**·A··k***·k*t¢.··kfr*
NOTE: Hepatitis C vi rus Genotype/Subtype assay is able to identify the
following subtypes:
1a, lb, la/lb, 1, Za/2c, 2b, 2, 3a, 3b, 3c, 3
4a, 4b, 4c/4d, 4e, 4f, 4h, 4, Sa, 6a, 10a
James Weisberger, MD
_ LABORATORY DIRECTOR
/ . T
Printed; O1/02/2006 14:28 -- End of Report -- I Pgt 2